Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
March 20 2024 - 7:00AM
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global
biotechnology company focused on developing and commercializing
novel medicines for rare diseases, today issued its fourth annual
Environmental, Social, and Governance (ESG) report. This year’s
report highlights the strength of the Company’s corporate
responsibility structure including increased efforts towards
transparency in our environmental reporting, our deep commitment to
ensuring broad and equitable access to our innovative therapies,
fostering an inclusive culture to ensure equal representation and
participation for all, and maintaining our leadership of strong
business ethics and integrity.
“Since the Company’s inception, it has been our
commitment to serve the needs of the rare disease community in
extraordinary ways,” stated Bradley Campbell, President and Chief
Executive Officer of Amicus Therapeutics, Inc. “Our annual ESG
report reinforces our dedication to patients, and also outlines our
obligation to support the needs of those beyond providing
next-generation therapies. Our investment in corporate
responsibility encompasses our philanthropic endeavors,
mission-focused and inclusive culture, environmental stewardship,
and strong business ethics and integrity. These core tenets, along
with our shared sense of purpose, allow us to meaningfully engage
with the rare disease community, and we look forward to building
upon this foundation and promise to communicate our progress
regularly and transparently.”
Amicus’ 2024 ESG initiatives are consistent with
those identified by the Sustainability Accounting Standards Board
(SASB) for the biotechnology and pharmaceuticals sector as well as
several United Nations (UN) Sustainable Development Goals which
most closely align with our patient-dedicated mission.
Highlights from the 2024 ESG
Report:
Environment. Committed to
practicing environmental responsibility and identifying and
implementing sustainability objectives in our operations, and with
our manufacturing and supply partners, to achieve a reduction in
greenhouse gas (GHG) emissions.
- Joined the CDP
Supply Chain Program to engage directly with our partners and
consolidate environmental information across our entire supply
chain.
- Continued to
have excellent oversight of climate-related risks by identifying
and implementing metrics to support oversight.
Patients. Continued to
prioritize our patient-focused mission to support individuals and
families affected by rare disease, meet the unmet needs of the rare
disease community, and support full access to education, diagnosis,
medication, and service provision for rare diseases.
- Delivered our
innovative medicines to >2,600 individuals worldwide through
commercial, clinical, and expanded access programs at the end of
2023.
- Collaborated
with internal and external stakeholders on strengthening health
equity in our clinical trials and the rare disease space.
Employees. Progressed and
enhanced our transparent, inclusive, and collaborative culture to
give employees the tools and resources to grow personally and
professionally while ensuring we can meaningfully engage with the
global rare disease community.
- Continued
efforts to support employee development, advancement, and retention
through our robust learning and leadership development
programs.
- In February
2024, Amicus was certified as a Great Place to Work in the United
States, United Kingdom, Italy, Germany, Spain, France, and
Japan.
Governance. Maintained a strong
culture of business ethics and integrity to ensure that the Company
is managed for the long-term benefit of all our stakeholders.
- Amicus Board of
Directors recognized by The Forum of Executive Women as a 2023
Champion of Board Diversity for having a Board of Directors where
women account for more than 30% of the Board.
- 100% of
employees received annual training on the Global Code of Conduct,
data protection cybersecurity, and social media.
- Robust Board oversight of risk and
the Enterprise Risk Management Program.
To access the full 2024 ESG Report, please visit
www.amicusrx.com/responsibility/environmental-social-governance/.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global,
patient-dedicated biotechnology company focused on discovering,
developing and delivering novel high-quality medicines for people
living with rare diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a pipeline of
cutting-edge, first- or best-in-class medicines for rare diseases.
For more information, please visit the company’s website at
www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors: Amicus Therapeutics Andrew
FaughnanVice President, Investor
Relationsafaughnan@amicusrx.com(609) 662-3809
Media: Amicus Therapeutics Diana Moore Head of
Global Corporate Affairs and Communicationsdmoore@amicusrx.com(609)
662-5079
FOLD-G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From May 2024 to Jun 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Jun 2023 to Jun 2024